Results of RTOG 94-08 finally published in NEJM

As we first reported in March 2010, when data were originally presented at the Genitourinary Cancers Symposium, RTOG 94-08 has shown that 4 months of androgen deprivation therapy (ADT) before and during external beam radiation therapy (EBRT) reduces the overall and the prostate cancer-specific mortality rates for men with localized prostate cancer (clinical stages T1b, T1c, T2a, or T2b). … READ MORE …

Short-term ADT with RT for localized prostate cancer

The RTOG 94-08 clinical trial was designed to test the idea that just 4 months of hormone therapy, administered  before and during radiation therapy, would improved the overall survival of patients diagnosed with clinical stage T1b-T2b prostate cancer and a PSA level equal to or lower than 20 ng/ml. … READ MORE …

Hormone therapy not helpful for low-risk patients receiving first-line radiation

A report presented yesterday in Chicago, at the annual meeting of the American Society for Radiation Oncology (ASTRO), suggests that short-term hormone therapy given prior to and during first-line radiation treatment to intermediate-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone. However, the same study also showed that there is no significant benefit for low-risk patients. … READ MORE …